3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one of the biggest biotechs on the planet, with a market cap of around $95 billion. But AbbVie is even bigger, with a market cap topping $112 billion.
There's one other key area where AbbVie holds an advantage over Gilead -- dividends. Both companies pay out dividends with attractive yields. However, here are three reasons why AbbVie is a better dividend stock than Gilead Sciences.
Image source: Getty Images.
Source: Fool.com
Gilead Sciences Inc Aktie
71,02 €
0,07 %
Eine klare Neigung zu Buy-Einschätzungen bei Gilead Sciences Inc, ohne Sell-Einschätzungen.
Ein Kursziel von 85 € für Gilead Sciences Inc zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 71.02 €.
